A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs MRNA 4157 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms KEYNOTE-603
- Sponsors Moderna Therapeutics
- 08 Jan 2019 Results published in the Moderna Therapeutics Media Release
- 17 Sep 2018 Planned End Date changed from 1 Mar 2020 to 1 Jun 2021.
- 08 Jan 2018 According to a Moderna Therapeutics media release, the company began dosing of patients in November 2017.